Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-133516

Published: 2020

Journal Articles

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Andrea Paterson, Matthew W. Jenner, John R. Jones, Mark T. Drayson, Roger G. Owen, Martin F. Kaiser, Walter M. Gregory, Faith E. Davies, J. Anthony Child, Gareth J. Morgan, Graham H. Jackson

Blood (2020) 136 (9): 1091–1104.

https://doi.org/10.1182/blood.2020005125

Published: 2020

Includes: Supplemental data

Journal Articles

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Kara-Louise Royle, MSc, David Cairns, MSc, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 1889.

https://doi.org/10.1182/blood-2019-126103

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 3132.

https://doi.org/10.1182/blood-2019-127469

Published: 2019

Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Blood (2018) 132 (23): 2465–2469.

https://doi.org/10.1182/blood-2018-06-857250

Published: 2018

Includes: Supplemental data

Journal Articles

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Pim Mutsaers, MD, Rowan Kuiper, MSc, Dora Hammerl, Msc, Mark van Duin, PhD, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Walter M Gregory, Jan J Cornelissen, MD PhD, Annemiek Broyl, MD PhD, Reno Debets, PhD, Pieter Sonneveld, MDPhD

Blood (2018) 132 (Supplement 1): 241.

https://doi.org/10.1182/blood-2018-99-118488

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

Charlotte A Bradbury, PhD MD FRCPath, FRCP, MSc, Matthew W Jenner, Alina Striha, MSc, Gordon Cook, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, John R Jones, MD, David Cairns, BSc, MSc, PhD, Anna Hockaday, Andrea Paterson, Mark T Drayson, MD PhD, Roger G Owen, MD, Martin F Kaiser, MD, Walter M Gregory, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Graham H Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 553.

https://doi.org/10.1182/blood.V130.Suppl_1.553.553

Published: 2017

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Gordon Cook, MD PhD, Kara-Louise Royle, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Anna Hockaday, Walter M Gregory, PhD, J Anthony Child, Faith E Davies, MD, Gareth J. Morgan, MD PhD, David Cairns, BSc, MSc, PhD, Graham Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 3063.

https://doi.org/10.1182/blood.V130.Suppl_1.3063.3063

Published: 2017

Journal Articles

Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Martin F Kaiser, MD, David Cairns, BSc, MSc, PhD, Alina Striha, MSc, John R Jones, MD, Vallari Shah, MBBS, Matthew W Jenner, Mark T Drayson, MD PhD, Roger G Owen, MD, Walter M Gregory, PhD, Gordon Cook, MD PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Faith E Davies, MD

Blood (2017) 130 (Supplement 1): 3040.

https://doi.org/10.1182/blood.V130.Suppl_1.3040.3040

Published: 2017

Journal Articles

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 1854.

https://doi.org/10.1182/blood.V130.Suppl_1.1854.1854

Published: 2017

NARROW

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only